Benoit P. Bouche

Operating Partner

Benoit, who joined Ampersand as an Operating Partner in 2022, serves as Chairman of the Board of P95 and Chairman of the Board for ProtaGene, a world leading CRO partner for the biopharmaceutical and cell and gene therapy industries and an Ampersand portfolio company. Previously, Benoit was President and CEO of Nexelis, an Ampersand portfolio company, which was acquired in January 2022 by Q2 Solutions, a leading global clinical trial laboratory services organization, and a wholly owned subsidiary of IQVIA, Inc. Benoit has a dual scientific (PharmD Pharmacy 1984; Ph.D. Pharmaceutical Sciences/Biotechnology 1986) and business (Advanced Management Program Harvard Business School 2002) education.